Lixte Stock Insiders

LIXT -  USA Stock  

USD 2.79  0.13  4.89%

Lixte Biotech employes about 3 people. The company is managed by 6 executives with total tenure of roughly 35 years, averaging almost 5.0 years of service per executive having 0.5 employees per reported executive. Break down Lixte Biotech management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Lixte Biotech Hlds future performance.
Additionally, see Stocks Correlation.

Search Insiders 

 
Refresh
  John Kovach  CEO
CEO, CFO, Director

Lixte Biotech Management Team Effectiveness

Lixte Biotech Hlds has return on total asset (ROA) of (56.61) % which means that it has lost $56.61 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (95.04) %, meaning that it created substantial loss on money invested by shareholders. Lixte Biotech management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Lixte Biotech Workforce Comparison

Lixte Biotech Hlds is rated below average in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 21,795. Lixte Biotech adds roughly 3.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.

Lixte Biotech Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lixte Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lixte Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Lixte Biotech insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Lixte Biotech Hlds Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Lixte Biotech Hlds Price Series Summation is a cross summation of Lixte Biotech price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Lixte Biotech Notable Stakeholders

A Lixte Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Lixte Biotech often face trade-offs trying to please all of them. Lixte Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Lixte Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
John Kovach - CEO, CFO, DirectorProfile
Stephen Forman - DirectorProfile
Kathleen Mullinix - Independent DirectorProfile
Philip Palmedo - Independent DirectorProfile
Winson Ho - DirectorProfile
Yun Yen - DirectorProfile

About Lixte Biotech Management Performance

The success or failure of an entity such as Lixte Biotech Hlds often depends on how effective the management is. Lixte Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Lixte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Lixte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was incorporated in 2005 and is based in East Setauket, New York. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.
The data published in Lixte Biotech's official financial statements usually reflect Lixte Biotech's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Lixte Biotech Hlds. For example, before you start analyzing numbers published by Lixte accountants, it's critical to develop an understanding of what Lixte Biotech's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Lixte Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lixte Biotech's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Lixte Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lixte Biotech Hlds. Please utilize our Beneish M Score to check the likelihood of Lixte Biotech's management to manipulate its earnings.

Lixte Biotech Workforce Analysis

Traditionally, organizations such as Lixte Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Lixte Biotech within its industry.

Lixte Biotech Manpower Efficiency

Return on Lixte Biotech Manpower

Revenue Per Employee66.7 K
Revenue Per Executive33.3 K
Net Loss Per Employee1.5 M
Net Loss Per Executive768.3 K
Working Capital Per Employee413 K
Working Capital Per Executive206.5 K
Additionally, see Stocks Correlation. Note that the Lixte Biotech Hlds information on this page should be used as a complementary analysis to other Lixte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for Lixte Stock analysis

When running Lixte Biotech Hlds price analysis, check to measure Lixte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotech is operating at the current time. Most of Lixte Biotech's value examination focuses on studying past and present price action to predict the probability of Lixte Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lixte Biotech's price. Additionally, you may evaluate how the addition of Lixte Biotech to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
The market value of Lixte Biotech Hlds is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotech's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotech's market value can be influenced by many factors that don't directly affect Lixte Biotech Hlds underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Lixte Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.